On February 25, Kechuang board Biomedical Company Nanjing Vazyme Biotech Co.Ltd(688105) disclosed the performance express of 2021. The report shows that last year, the company achieved an operating revenue of 1.864 billion yuan, an increase of 19.13% over the same period of the previous year. Among them, the sales revenue of covid-19 related businesses (including diagnostic raw materials and terminal detection reagents) reached about 1.146 billion yuan, accounting for 61.48% of the operating revenue.
As a leading enterprise of domestic molecular biological reagents, Nanjing Vazyme Biotech Co.Ltd(688105) has obvious advantages in the fields of scientific research, diagnosis and sequencing, and continues to expand product categories and application scenarios. It is in a period of rapid growth in recent years. It is reported that during the reporting period, thanks to China’s covid-19 epidemic prevention policy, the business development of the main customer groups of the company’s routine business returned to normal and recovered in time during the reporting period. The company’s conventional businesses including scientific research reagents, sequencing reagents, diagnostic raw materials, diagnostic reagents and instruments, cro services, etc. achieved a sales revenue of 718 million yuan, an increase of about 92% compared with the same period in 2020.
It is worth mentioning that due to the complete categories of covid-19 products and the repeated fluctuations of global covid-19 epidemic during the reporting period, the sales revenue of covid-19 related businesses (including diagnostic raw materials and terminal detection reagents) of the company reached about 1.146 billion yuan in 2021, which was basically the same year-on-year.
In terms of covid-19 business development, Guolian Securities Co.Ltd(601456) analysis shows that, “The market is concerned that covid-19 will bring about rapid growth of short-term performance and worry about long-term performance. We believe that the company still has huge growth space in the future and full of endogenous power. The management has a strong sense of market and foresight. Since the establishment of the company, the company can successfully enter a new segment every one to two years. At the same time, we believe that the direct sales network is the core competition for the rapid growth of the company power. The company has a sales team of more than 600 people, which can obtain customer demand information more directly and effectively than the distribution mode of other companies, and the economies of scale of sales are prominent. “
